ZyVersa Therapeutics reported total assets of $0.74M and total liabilities of $14.87M for the quarter ended Mar 2026, down 96.5% year over year. This balance sheet covers 16 quarters of results from Mar 2022 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Balance SheetBalance Sheet | Mar2022 | Jun2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Current Assets | ||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 0.83M | 0.34M | 5.90M | 1.28M | 0.23M | 1.58M | 3.14M | 2.03M | 0.12M | 0.12M | 1.53M | 1.61M | 0.07M | 0.53M | 0.10M | 0.30M |
| Cash & Current Investments | 0.83M | 0.34M | 5.90M | 1.28M | 0.23M | 1.58M | 3.14M | 2.03M | 0.12M | 0.12M | 1.53M | 1.61M | 0.07M | 0.53M | 0.10M | 0.30M |
| Prepaid Assets | 0.23M | 0.23M | 0.23M | 1.32M | 0.89M | 0.43M | 0.22M | 0.87M | 0.52M | 0.27M | 0.18M | 0.50M | 0.38M | 0.30M | 0.35M | 0.44M |
| Current Assets | 1.06M | 0.57M | 6.36M | 2.83M | 1.12M | 2.01M | 3.35M | 2.90M | 0.64M | 0.39M | 1.72M | 2.11M | 0.55M | 1.00M | 0.46M | 0.74M |
| Non-Current Assets | ||||||||||||||||
| Property, Plant & Equipment (Net)PP&E (Net) | 0.02M | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M | 0.00M | |||||||||
| Long-Term Investments | 78.45M | 78.56M | ||||||||||||||
| Goodwill | 11.90M | 11.90M | 11.90M | |||||||||||||
| Intangibles | 100.09M | 30.81M | 81.40M | |||||||||||||
| Goodwill & Intangibles | 111.98M | 11.90M | 11.90M | 30.81M | 81.40M | |||||||||||
| Other Non-Current Assets | 0.17M | 0.10M | 100.13M | 100.13M | 30.81M | 18.65M | 18.65M | 18.65M | 18.86M | 18.88M | 18.70M | 0.44M | 0.04M | |||
| Non-Current Assets | 78.62M | 78.66M | 112.14M | 112.12M | 30.87M | 30.85M | 18.76M | 18.75M | 18.83M | 19.03M | 18.88M | 18.88M | 19.09M | 0.04M | ||
| Assets | 79.67M | 79.23M | 118.51M | 114.95M | 31.99M | 32.85M | 22.11M | 21.65M | 19.47M | 19.42M | 20.60M | 20.99M | 19.64M | 1.04M | 0.46M | 0.74M |
| Liabilities | ||||||||||||||||
| Current Liabilities | ||||||||||||||||
| Accounts Payables | 6.03M | 6.38M | 8.14M | 8.90M | 8.43M | 8.13M | 8.32M | 9.28M | 9.34M | 9.60M | 9.77M | 9.81M | 10.12M | 10.24M | ||
| Notes Payables | 1.20M | |||||||||||||||
| Payables | 6.03M | 6.38M | 8.14M | 8.90M | 8.43M | 8.13M | 8.32M | 9.28M | 9.34M | 9.60M | 9.77M | 9.81M | 10.12M | 11.44M | ||
| Accumulated Expenses | 0.83M | 0.78M | 2.05M | 2.11M | 2.28M | 2.78M | 1.75M | 1.45M | 1.68M | 2.26M | 1.89M | 2.40M | 2.92M | 2.96M | 2.73M | 3.30M |
| Total Current Liabilities | 0.83M | 0.78M | 8.19M | 8.58M | 10.48M | 11.71M | 10.19M | 9.58M | 9.99M | 11.54M | 11.23M | 12.00M | 12.69M | 12.77M | 12.85M | 14.87M |
| Non-Current Liabilities | ||||||||||||||||
| Preferred Stock Liabilities | 78.45M | 78.45M | 0.33M | |||||||||||||
| Non-Current Deferred Tax LiabilityNon-Current Deferred Tax | 10.32M | 9.28M | 1.44M | 1.44M | 0.84M | 0.84M | 0.85M | 0.85M | 0.85M | 0.85M | 0.85M | |||||
| Other Non-Current Liabilities | 3.38M | 3.38M | 0.13M | |||||||||||||
| Total Non-Current Liabilities | 79.28M | 79.22M | 18.84M | 17.86M | 11.93M | 13.15M | 14.74M | |||||||||
| Total Liabilities | 82.65M | 82.60M | 18.84M | 17.86M | 11.93M | 13.15M | 11.04M | 10.43M | 10.85M | 12.40M | 12.08M | 12.86M | 13.54M | 12.77M | 12.85M | 14.87M |
| Shareholder's Equity | ||||||||||||||||
| Total Debt | 1.20M | |||||||||||||||
| Common Equity | -2.98M | -3.37M | 99.66M | 97.10M | 20.06M | 19.70M | 11.07M | 11.22M | 8.62M | 7.03M | 8.52M | 8.13M | 6.10M | -11.73M | -12.39M | -14.12M |
| Liabilities and Shareholders Equity | 79.67M | 79.23M | 118.51M | 114.95M | 31.99M | 32.85M | 22.11M | 21.65M | 19.47M | 19.42M | 20.60M | 20.99M | 19.64M | 1.04M | 0.46M | 0.74M |
| Treasury Shares | 0.00M | 0.00M | -7.00 | -7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | ||||
| Retained Earnings | -2.98M | -3.37M | -4.92M | -8.50M | -87.00M | -89.90M | -103.22M | -106.05M | -108.81M | -111.21M | -112.63M | -114.90M | -117.10M | -136.91M | -137.58M | -139.40M |
| Preferred Shares | 1.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Pull ZyVersa Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=ZVSA&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "ZVSA", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=ZVSA&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();